Wall Street brokerages expect that MEDNAX Inc (NYSE:MD) will post earnings per share of $0.84 for the current fiscal quarter, Zacks reports. Seven analysts have provided estimates for MEDNAX’s earnings. The highest EPS estimate is $0.88 and the lowest is $0.75. MEDNAX reported earnings per share of $0.75 in the same quarter last year, which suggests a positive year over year growth rate of 12%. The business is expected to issue its next quarterly earnings results on Thursday, April 19th.
On average, analysts expect that MEDNAX will report full-year earnings of $4.22 per share for the current year, with EPS estimates ranging from $4.02 to $4.35. For the next year, analysts forecast that the company will report earnings of $4.50 per share, with EPS estimates ranging from $4.32 to $4.73. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for MEDNAX.
MEDNAX (NYSE:MD) last announced its quarterly earnings results on Thursday, February 8th. The company reported $0.87 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.83 by $0.04. The company had revenue of $910.82 million during the quarter, compared to the consensus estimate of $884.55 million. MEDNAX had a net margin of 9.26% and a return on equity of 10.10%. The firm’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter last year, the firm earned $1.00 earnings per share.
Several equities research analysts recently issued reports on MD shares. Piper Jaffray Companies started coverage on shares of MEDNAX in a report on Wednesday, December 13th. They issued an “overweight” rating and a $58.00 target price on the stock. SunTrust Banks set a $55.00 target price on shares of MEDNAX and gave the stock a “hold” rating in a report on Thursday, December 21st. Zacks Investment Research upgraded shares of MEDNAX from a “hold” rating to a “buy” rating and set a $60.00 target price on the stock in a report on Tuesday, January 23rd. Stifel Nicolaus restated a “hold” rating and issued a $56.00 target price on shares of MEDNAX in a report on Wednesday, January 24th. Finally, Mizuho set a $49.00 target price on shares of MEDNAX and gave the stock a “hold” rating in a report on Wednesday, January 24th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the stock. MEDNAX presently has a consensus rating of “Hold” and an average target price of $55.58.
Shares of MEDNAX (NYSE:MD) traded down $0.01 on Friday, hitting $57.46. 800,078 shares of the company traded hands, compared to its average volume of 908,024. MEDNAX has a 12 month low of $40.56 and a 12 month high of $70.72. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $5,389.52, a P/E ratio of 18.30, a P/E/G ratio of 1.42 and a beta of 0.26.
In other news, insider John C. Pepia sold 3,000 shares of MEDNAX stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $58.35, for a total transaction of $175,050.00. Following the transaction, the insider now owns 39,716 shares in the company, valued at approximately $2,317,428.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 2.40% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. GHP Investment Advisors Inc. boosted its stake in shares of MEDNAX by 13.8% during the 4th quarter. GHP Investment Advisors Inc. now owns 7,735 shares of the company’s stock worth $413,000 after acquiring an additional 940 shares during the last quarter. Amalgamated Bank boosted its stake in shares of MEDNAX by 5.9% during the 4th quarter. Amalgamated Bank now owns 18,448 shares of the company’s stock worth $986,000 after acquiring an additional 1,035 shares during the last quarter. American International Group Inc. boosted its stake in shares of MEDNAX by 0.6% during the 3rd quarter. American International Group Inc. now owns 195,583 shares of the company’s stock worth $8,434,000 after acquiring an additional 1,263 shares during the last quarter. Swiss National Bank boosted its stake in shares of MEDNAX by 0.4% during the 3rd quarter. Swiss National Bank now owns 343,000 shares of the company’s stock worth $14,790,000 after acquiring an additional 1,300 shares during the last quarter. Finally, Macquarie Group Ltd. boosted its stake in shares of MEDNAX by 36.1% during the 4th quarter. Macquarie Group Ltd. now owns 4,900 shares of the company’s stock worth $262,000 after acquiring an additional 1,300 shares during the last quarter. Institutional investors and hedge funds own 98.53% of the company’s stock.
WARNING: This story was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.thelincolnianonline.com/2018/03/19/mednax-inc-md-expected-to-post-earnings-of-0-84-per-share.html.
MEDNAX Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.